Laboratorios Farmaceuticos Rovi
Laboratorios Farmaceuticos Rovi, S.A. produces and sells pharmaceutical products in Spain and internationally. The last earnings update was 70 days ago. More info.
Add to Portfolio Compare Print
ROVI Share Price and Events
7 Day Returns
1 Year Returns
ROVI Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Laboratorios Farmaceuticos Rovi (ROVI) | 0.3% | 0% | 8.7% | 19% | 43.8% | 116.2% |
| Europe Pharmaceuticals | -2.4% | -0.4% | 3.5% | 3.6% | 2.1% | 8.4% |
| ES Market | 0.9% | 1.7% | -0.8% | -3.3% | 12.3% | -13% |
1 Year Return vs Industry and Market
- ROVI outperformed the Pharmaceuticals industry which returned 3.6% over the past year.
- ROVI outperformed the Market in Spain which returned -3.3% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Laboratorios Farmaceuticos Rovi
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Laboratorios Farmaceuticos Rovi.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 6 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.4% |
| Perpetual Growth Rate | 10-Year ES Government Bond Rate | 1.5% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year ES Govt Bond Rate | 1.5% |
| Equity Risk Premium | S&P Global | 8.2% |
| Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 0.73 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.733 (1 + (1- 25%) (4.58%)) |
0.838 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.84 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.53% + (0.838 * 8.18%) |
8.38% |
Discounted Cash Flow Calculation for BME:ROVI using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Laboratorios Farmaceuticos Rovi is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (EUR, Millions) | Source |
Present Value Discounted (@ 8.38%) |
|
|---|---|---|---|
| 2020 | 23.40 | Analyst x3 | 21.59 |
| 2021 | 41.50 | Analyst x3 | 35.33 |
| 2022 | 66.60 | Analyst x2 | 52.31 |
| 2023 | 65.10 | Analyst x1 | 47.18 |
| 2024 | 64.36 | Est @ -1.14% | 43.04 |
| 2025 | 64.14 | Est @ -0.34% | 39.57 |
| 2026 | 64.28 | Est @ 0.22% | 36.60 |
| 2027 | 64.68 | Est @ 0.61% | 33.97 |
| 2028 | 65.25 | Est @ 0.89% | 31.62 |
| 2029 | 65.95 | Est @ 1.08% | 29.49 |
| Present value of next 10 years cash flows | €370.71 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2029
× (1 + g) ÷ (Discount Rate – g)
= €65.95 × (1 + 1.53%) ÷ (8.38% – 1.53%) |
€976.80 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= €976.80 ÷ (1 + 8.38%)10 |
€436.79 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= €370.71 + €436.79 |
€807.50 |
| Equity Value per Share (EUR) |
= Total value / Shares Outstanding
= €807.50 / 55.37 |
€14.58 |
| Calculation | Result | |
|---|---|---|
| Value per share (EUR) | From above. | €14.58 |
| Current discount | Discount to share price of
€20.00
= -1 x (€20.00 - €14.58) / €14.58 |
-37.1% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Laboratorios Farmaceuticos Rovi is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Laboratorios Farmaceuticos Rovi's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Laboratorios Farmaceuticos Rovi's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in EUR | €0.35 |
| BME:ROVI Share Price ** | BME (2019-07-17) in EUR | €20 |
| Europe Pharmaceuticals Industry PE Ratio | Median Figure of 44 Publicly-Listed Pharmaceuticals Companies | 22.3x |
| Spain Market PE Ratio | Median Figure of 141 Publicly-Listed Companies | 17.33x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Laboratorios Farmaceuticos Rovi.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = BME:ROVI Share Price ÷ EPS (both in EUR) = 20 ÷ 0.35 |
57.25x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Laboratorios Farmaceuticos Rovi is overvalued based on earnings compared to the Europe Pharmaceuticals industry average.
- Laboratorios Farmaceuticos Rovi is overvalued based on earnings compared to the Spain market.
Price based on expected Growth
Does
Laboratorios Farmaceuticos Rovi's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 57.25x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts |
44.2%per year |
| Europe Pharmaceuticals Industry PEG Ratio | Median Figure of 35 Publicly-Listed Pharmaceuticals Companies | 2.02x |
| Spain Market PEG Ratio | Median Figure of 82 Publicly-Listed Companies | 1.61x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 57.25x ÷ 44.2% |
1.3x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Laboratorios Farmaceuticos Rovi is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Laboratorios Farmaceuticos Rovi's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in EUR | €5.19 |
| BME:ROVI Share Price * | BME (2019-07-17) in EUR | €20 |
| Europe Pharmaceuticals Industry PB Ratio | Median Figure of 95 Publicly-Listed Pharmaceuticals Companies | 3.07x |
| Spain Market PB Ratio | Median Figure of 185 Publicly-Listed Companies | 1.61x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = BME:ROVI Share Price ÷ Book Value per Share (both in EUR) = 20 ÷ 5.19 |
3.85x |
* Primary Listing of Laboratorios Farmaceuticos Rovi.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Laboratorios Farmaceuticos Rovi is overvalued based on assets compared to the Europe Pharmaceuticals industry average.
Value checks
We assess Laboratorios Farmaceuticos Rovi's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Laboratorios Farmaceuticos Rovi has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Laboratorios Farmaceuticos Rovi's earnings growth is expected to exceed the low risk savings rate of 1.5%.
Growth vs Market Checks
- Laboratorios Farmaceuticos Rovi's earnings growth is expected to exceed the Spain market average.
- Laboratorios Farmaceuticos Rovi's revenue growth is expected to exceed the Spain market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| BME:ROVI Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts | 44.2% |
| BME:ROVI Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts | 13.7% |
| Europe Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 12.5% |
| Europe Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 4.8% |
| Spain Market Earnings Growth Rate | Market Cap Weighted Average | 7.9% |
| Spain Market Revenue Growth Rate | Market Cap Weighted Average | 4.1% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | ||||
| 2022-12-31 | 549 | 98 | 93 | 1 |
| 2021-12-31 | 439 | 55 | 55 | 3 |
| 2020-12-31 | 380 | 46 | 42 | 6 |
| 2019-12-31 | 346 | 16 | 17 | 4 |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 310 | 3 | 18 |
| 2018-12-31 | 303 | 9 | 18 |
| 2018-09-30 | 291 | 8 | 16 |
| 2018-06-30 | 283 | 16 | 9 |
| 2018-03-31 | 284 | 30 | 18 |
| 2017-12-31 | 276 | 18 | 17 |
| 2017-09-30 | 277 | 21 | 22 |
| 2017-06-30 | 275 | 25 | 24 |
| 2017-03-31 | 272 | 24 | 23 |
| 2016-12-31 | 265 | 46 | 26 |
| 2016-09-30 | 260 | 44 | 25 |
| 2016-06-30 | 254 | 38 | 24 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
All data from Laboratorios Farmaceuticos Rovi Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | ||||
| 2022-12-31 | 1.68 | 1.68 | 1.68 | 1.00 |
| 2021-12-31 | 0.99 | 1.07 | 0.91 | 3.00 |
| 2020-12-31 | 0.78 | 1.30 | 0.38 | 6.00 |
| 2019-12-31 | 0.30 | 0.39 | 0.25 | 3.00 |
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2019-03-31 | |
| 2018-12-31 | 0.35 |
| 2018-09-30 | |
| 2018-06-30 | 0.18 |
| 2018-03-31 | |
| 2017-12-31 | 0.35 |
| 2017-09-30 | |
| 2017-06-30 | 0.48 |
| 2017-03-31 | |
| 2016-12-31 | 0.53 |
| 2016-09-30 | |
| 2016-06-30 | 0.49 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Laboratorios Farmaceuticos Rovi is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Future performance checks
We assess Laboratorios Farmaceuticos Rovi's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Laboratorios Farmaceuticos Rovi has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Laboratorios Farmaceuticos Rovi performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Laboratorios Farmaceuticos Rovi's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Laboratorios Farmaceuticos Rovi's 1-year earnings growth exceeds its 5-year average (1.4% vs -8.2%)
- Laboratorios Farmaceuticos Rovi's earnings growth has not exceeded the Europe Pharmaceuticals industry average in the past year (1.4% vs 13.8%).
Earnings and Revenue History
All data from Laboratorios Farmaceuticos Rovi Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 309.59 | 17.95 | 90.78 | |
| 2018-12-31 | 303.20 | 17.90 | 91.10 | |
| 2018-09-30 | 291.13 | 15.87 | 89.91 | |
| 2018-06-30 | 283.20 | 9.03 | 87.92 | |
| 2018-03-31 | 283.96 | 17.71 | 86.52 | |
| 2017-12-31 | 275.65 | 17.24 | 84.60 | |
| 2017-09-30 | 277.12 | 21.59 | 80.77 | |
| 2017-06-30 | 275.07 | 23.84 | 81.45 | |
| 2017-03-31 | 271.96 | 23.06 | 80.46 | |
| 2016-12-31 | 265.17 | 26.09 | 80.14 | |
| 2016-09-30 | 259.82 | 24.81 | 84.03 | |
| 2016-06-30 | 253.61 | 24.24 | 84.29 | |
| 2016-03-31 | 245.91 | 22.76 | 84.59 | |
| 2015-12-31 | 246.01 | 19.81 | 84.43 | |
| 2015-09-30 | 242.40 | 20.76 | 53.28 | -8.87 |
| 2015-06-30 | 243.00 | 22.73 | 78.12 | |
| 2015-03-31 | 241.19 | 24.64 | 76.47 | |
| 2014-12-31 | 238.05 | 24.12 | 75.45 | |
| 2014-09-30 | 229.95 | 24.21 | 76.88 | 1.08 |
| 2014-06-30 | 224.28 | 24.15 | 77.40 | |
| 2014-03-31 | 221.43 | 23.61 | 77.81 | |
| 2013-12-31 | 217.59 | 23.02 | 76.10 | |
| 2013-09-30 | 209.27 | 21.56 | 102.50 | 7.79 |
| 2013-06-30 | 206.66 | 20.39 | 75.75 | |
| 2013-03-31 | 204.76 | 19.60 | 75.50 | |
| 2012-12-31 | 201.92 | 19.51 | 75.03 | |
| 2012-09-30 | 198.12 | 19.01 | 74.02 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Laboratorios Farmaceuticos Rovi has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Laboratorios Farmaceuticos Rovi used its assets less efficiently than the Europe Pharmaceuticals industry average last year based on Return on Assets.
- Laboratorios Farmaceuticos Rovi's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Laboratorios Farmaceuticos Rovi's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Laboratorios Farmaceuticos Rovi has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Laboratorios Farmaceuticos Rovi's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Laboratorios Farmaceuticos Rovi's finances.
The net worth of a company is the difference between its assets and liabilities.
- Laboratorios Farmaceuticos Rovi is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Laboratorios Farmaceuticos Rovi's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 8.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Laboratorios Farmaceuticos Rovi Company Filings, last reported 3 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 294.45 | 29.75 | 71.31 |
| 2018-12-31 | 287.47 | 34.22 | 95.58 |
| 2018-09-30 | 201.10 | 39.52 | 17.47 |
| 2018-06-30 | 193.11 | 38.46 | 30.03 |
| 2018-03-31 | 198.63 | 40.42 | 38.97 |
| 2017-12-31 | 191.69 | 43.24 | 40.75 |
| 2017-09-30 | 191.44 | 47.10 | 44.17 |
| 2017-06-30 | 190.12 | 49.14 | 54.15 |
| 2017-03-31 | 190.02 | 51.30 | 47.66 |
| 2016-12-31 | 183.41 | 33.79 | 41.41 |
| 2016-09-30 | 179.01 | 37.63 | 40.72 |
| 2016-06-30 | 175.50 | 39.72 | 44.67 |
| 2016-03-31 | 173.98 | 41.44 | 39.93 |
| 2015-12-31 | 164.79 | 42.78 | 29.31 |
| 2015-09-30 | 162.23 | 44.15 | 25.58 |
| 2015-06-30 | 159.27 | 35.04 | 25.74 |
| 2015-03-31 | 165.14 | 35.94 | 27.86 |
| 2014-12-31 | 158.47 | 36.31 | 26.73 |
| 2014-09-30 | 154.49 | 37.29 | 28.24 |
| 2014-06-30 | 151.16 | 25.21 | 25.28 |
| 2014-03-31 | 149.97 | 30.23 | 12.87 |
| 2013-12-31 | 144.46 | 30.98 | 19.46 |
| 2013-09-30 | 140.22 | 31.53 | 17.07 |
| 2013-06-30 | 133.39 | 32.05 | 22.42 |
| 2013-03-31 | 132.48 | 38.09 | 22.19 |
| 2012-12-31 | 126.45 | 38.39 | 16.65 |
| 2012-09-30 | 123.57 | 38.52 | 21.62 |
- Laboratorios Farmaceuticos Rovi's level of debt (10.1%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has been reduced over the past 5 years (20.1% vs 10.1% today).
- Debt is not well covered by operating cash flow (9.5%, less than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 24x coverage).
Financial health checks
We assess Laboratorios Farmaceuticos Rovi's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Laboratorios Farmaceuticos Rovi has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Laboratorios Farmaceuticos Rovi
shares you are expected to receive
€8
in your first year as a dividend.
Dividend Amount
- Laboratorios Farmaceuticos Rovi's pays a lower dividend yield than the bottom 25% of dividend payers in Spain (2.3%).
- Laboratorios Farmaceuticos Rovi's dividend is below the markets top 25% of dividend payers in Spain (5.31%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
| Europe Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 31 Stocks | 3.3% |
| Spain Market Average Dividend Yield | Market Cap Weighted Average of 77 Stocks | 4.3% |
| Spain Minimum Threshold Dividend Yield | 10th Percentile | 1.2% |
| Spain Bottom 25% Dividend Yield | 25th Percentile | 2.3% |
| Spain Top 25% Dividend Yield | 75th Percentile | 5.3% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | 0.41 | 1.00 |
| 2021-12-31 | 0.29 | 3.00 |
| 2020-12-31 | 0.19 | 6.00 |
| 2019-12-31 | 0.07 | 4.00 |
| Date (Data in €) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-02-26 | 0.080 | 0.423 |
| 2018-02-20 | 0.121 | 0.717 |
| 2017-02-16 | 0.183 | 1.169 |
| 2016-02-24 | 0.139 | 1.042 |
| 2015-02-25 | 0.169 | 1.196 |
| 2014-02-27 | 0.161 | 1.688 |
| 2013-11-07 | 0.137 | 1.416 |
| 2013-07-31 | 0.137 | 1.709 |
| 2013-04-24 | 0.137 | 1.968 |
| 2013-02-20 | 0.137 | 2.052 |
| 2012-11-08 | 0.127 | 2.325 |
| 2012-07-26 | 0.127 | 2.443 |
| 2012-04-26 | 0.127 | 2.546 |
| 2012-02-23 | 0.127 | 2.602 |
| 2011-05-11 | 0.172 | 3.342 |
| 2011-02-24 | 0.172 | 3.398 |
| 2011-02-23 | 0.172 | 3.335 |
| 2010-07-29 | 0.141 | 2.872 |
| 2010-02-24 | 0.141 | 2.698 |
| 2010-01-04 | 0.141 | 1.975 |
| 2009-07-29 | 0.165 | 2.121 |
| 2009-02-26 | 0.165 | 3.133 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Laboratorios Farmaceuticos Rovi is not paying a notable dividend for Spain, therefore no need to check if the payments are stable.
- Laboratorios Farmaceuticos Rovi is not paying a notable dividend for Spain, therefore no need to check if the payments are increasing.
Income/ dividend checks
We assess Laboratorios Farmaceuticos Rovi's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Laboratorios Farmaceuticos Rovi afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Laboratorios Farmaceuticos Rovi has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | €524,000 |
| TENURE AS CEO | 2.5 years |
CEO Bio
Mr. Juan López-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007. Mr. Encina has been with Laboratorios Farmaceuticos ROVI since 1994 and served as its General Director since October 2001. Mr. López-Belmonte Encina began his career carrying out diverse roles for various international pharmaceutical companies including the Nielzen Group in Spain, the Tyco Group in the United States and Boots Pharmaceutical in the United Kingdom. He has been Chairman of Board of Directors of Laboratorios Farmaceuticos ROVI for over 13 years. He has been a Director of Laboratorios Farmaceuticos ROVI, S.A. since July 27, 2007. He is a Member of the Board of Directors of the Madrid Chamber of Commerce, the Andalusia Technology Corporation Association, the Board of Directors and Executive Committee of Madrid Business Confederation and a member of the Management Board of ANEFP. Mr. López-Belmonte Encina Holds a Degree in Business and Economics from CEU San Pablo de Madrid, with an emphasis in auditing.
CEO Compensation
- Juan's compensation has been consistent with company performance over the past year, both up more than 20%.
- Juan's remuneration is higher than average for companies of similar size in Spain.
Management Team Tenure
Average tenure of the Laboratorios Farmaceuticos Rovi management team in years:
- The average tenure for the Laboratorios Farmaceuticos Rovi management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team
Juan Encina
CEO & Director
€524K
2.5 yrs
Iván López-Belmonte Encina
First Deputy Chairman & Corporate Development Manager
€406K
Javier López-Belmonte Encina
Second Deputy Chairman & CFO
€404K
18.5 yrs
Mercedes del Castillo Sánchez
Legal Department Manager
Fernando Martínez Morales
Director of Sales
9.8 yrs
Rosario Perucha Pérez
Marketing Manager
Francisco Angulo García
Human Resources Manager
Gabriel Fernández
Secretary
Ignacio Toledano
Deputy Secretary
1.5 yrs
Board of Directors Tenure
Average tenure of the Laboratorios Farmaceuticos Rovi board of directors in years:
- The tenure for the Laboratorios Farmaceuticos Rovi board of directors is about average.
Board of Directors
Juan López
Chairman
€150K
Juan Encina
CEO & Director
€524K
12 yrs
Iván López-Belmonte Encina
First Deputy Chairman & Corporate Development Manager
€406K
3.7 yrs
Javier López-Belmonte Encina
Second Deputy Chairman & CFO
€404K
3.7 yrs
Enrique Castellón Leal
Independent Director
€60K
11.8 yrs
José de Almansa Moreno-Barreda
Independent Director
€60K
4.1 yrs
Marcos Peña Pinto
Director
0.2 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Laboratorios Farmaceuticos Rovi's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Laboratorios Farmaceuticos Rovi has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
BME:ROVI Historical Debt, July 5th 2019 A Look At Laboratorios Farmaceuticos Rovi's Liabilities According to the last reported balance sheet, Laboratorios Farmaceuticos Rovi had liabilities of €89.4m due within 12 months, and liabilities of €43.8m due beyond 12 months. … Given that Laboratorios Farmaceuticos Rovi has more cash than debt, we're pretty confident it can manage its debt safely. … While Laboratorios Farmaceuticos Rovi has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance.
Simply Wall St - – Full articleWhat Should You Know About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Earnings Trajectory?
In December 2018, Laboratorios Farmaceuticos Rovi, S.A. … (BME:ROVI) announced its latest earnings update, whicha
Simply Wall St - – Full articleWhat Does Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) P/E Ratio Tell You?
We'll show how you can use Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) P/E ratio to inform your assessment of the investment opportunity. … Laboratorios Farmaceuticos Rovi has a P/E ratio of 52.53, based on the last twelve months. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleShould Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Focus On Improving This Fundamental Metric?
By way of learning-by-doing, we'll look at ROE to gain a better understanding of Laboratorios Farmaceuticos Rovi, S.A. … Laboratorios Farmaceuticos Rovi has a ROE of 7.9%, based on the last twelve months. … Check out our latest analysis for Laboratorios Farmaceuticos Rovi?
Simply Wall St - – Full articleWhat You Must Know About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Financial Strength
(BME:ROVI) is a small-cap stock with a market capitalization of €1.0b. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … So, understanding the company's financial health becomes
Simply Wall St - – Full articleCalculating The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
by taking the foreast future cash flows of the company and discounting them back to today's value. … Discounted Cash Flows (DCF). … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model
Simply Wall St - – Full articleWhy Laboratorios Farmaceuticos Rovi SA (BME:ROVI) Delivered An Inferior ROE Compared To The Industry
This analysis is intended to introduce important early concepts to people who are starting to invest. … Laboratorios Farmaceuticos Rovi SA’s (BME:ROVI) most recent return on equity was a substandard 4.7% relative to its industry performance of 14.6% over the past year. … Check out our latest analysis for Laboratorios Farmaceuticos Rovi
Simply Wall St - – Full articleDoes Laboratorios Farmaceuticos Rovi SA's (BME:ROVI) PE Ratio Signal A Selling Opportunity?
Laboratorios Farmaceuticos Rovi SA (BME:ROVI) is trading with a trailing P/E of 45.8x, which is higher than the industry average of 23.2x. … Although some investors may jump to the conclusion that you should avoid the stock or sell if you own it, understanding the assumptions behind the P/E ratio might change your mind. … View our latest analysis for Laboratorios Farmaceuticos Rovi
Simply Wall St - – Full articleWhat Do Investors Need To Know About The Future Of Laboratorios Farmaceuticos Rovi SA's (BME:ROVI)?
After Laboratorios Farmaceuticos Rovi SA's (BME:ROVI) recent earnings announcement in March 2018, … as a -8.95% fall in profits is expected in the upcoming year … the past 5-year average growth rate of 2.69%.
Simply Wall St - – Full articleIs Laboratorios Farmaceuticos Rovi SA's (BME:ROVI) PE Ratio A Signal To Sell For Investors?
But can investors make a closing judgement of the company’s value based on this bigger multiple. … The answer is no, since important variables like the company’s potential to grow and debt levels are ignored in the PE’s calculation … To resolve this problem, I’ll identify some important factors to consider when judging the relative valuation of
Simply Wall St - – Full articleCompany Info
Description
Laboratorios Farmaceuticos Rovi, S.A. produces and sells pharmaceutical products in Spain and internationally. The company’s principal product is Bemiparin, a low molecular weight heparin. Its prescription products comprise Hibor to prevent thromboembolic disease; Hirobriz, Breezhale, and Ulunar Breezhaler for chronic obstructive pulmonary disease; Volutsa for the treatment of moderate to severe storage systems symptoms; and Medikinet and Medicebran for attention deficit and hyperactivity disorder. The company’s prescription products also include Exxiv for the symptoms of rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis; Neparvis for treatment of symptomatic chronic heart failure with reduced ejection; Absorcol, Vytorin, and Orvatez, and for hypercholesterolaemia; and Mysimba for the obesity treatment. In addition, it offers diagnostic products, such as SonoVue for use in ultrasound imaging; Iopamiro and Iomeron computed tomography and intervention; Multihance and Prohance for use in diagnostic magnetic resonance imaging; and EmpowerCTA, EmpowerMR, and CT Exprès contrast injection systems and compatible disposable material. Further, the company provides OTC products. Additionally, it distributes products licensed from other laboratories. The company was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
Details
| Name: | Laboratorios Farmaceuticos Rovi, S.A. |
| ROVI | |
| Exchange: | BME |
| Founded: | 1946 |
| €1,107,478,200 | |
| 55,373,910 | |
| Website: | http://www.rovi.es |
| Address: |
Laboratorios Farmaceuticos Rovi, S.A. Calle José Isbert, 2, Madrid, Madrid, 28223, Spain |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| BME | ROVI | Nominative Shares | Bolsas y Mercados Espanoles | ES | EUR | 18. Dec 2007 | |
| DB | 41L | Nominative Shares | Deutsche Boerse AG | DE | EUR | 18. Dec 2007 | |
| BST | 41L | Nominative Shares | Boerse-Stuttgart | DE | EUR | 18. Dec 2007 | |
| LSE | 0ILL | Nominative Shares | London Stock Exchange | GB | EUR | 18. Dec 2007 | |
| BATS-CHIXE | ROVIE | Nominative Shares | BATS 'Chi-X Europe' | GB | EUR | 18. Dec 2007 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/07/17 21:07 |
| End of day share price update: | 2019/07/17 00:00 |
| Last estimates confirmation: | 2019/07/05 |
| Last earnings filing: | 2019/05/08 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
